New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Heatwurx Inc.

PCSA

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

1.67 0.03 −1.76%
Market cap
$4.8M
P/E
n/m
Fwd P/E FY16e
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
0.4×
Payout ratio
—

Heatwurx Inc. (PCSA) Return on invested capital

Alert me on Return on invested capital

Heatwurx Inc.'s return on invested capital over the twelve months to 30 September 2026 was 0.00%, up 21694.3 percentage points from fiscal 2025 (−21,694.3%). Over the past ten years it has ranged from −21,694.3% (fiscal 2025) to 0.00% (fiscal 2017) — the current reading is the lowest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.

Return on invested capital, annual

Embed this chart

Annual newest first

Period Return on invested capital Change (points)
FY2025 −21,694.3% (20,202.54)
FY2024 −1,491.8% 1,038.50
FY2023 −2,530.3% (1,221.13)
FY2022 −1,309.2% (1,224.77)
FY2021 −84.4% 40.62
FY2020 −125.0% (95.26)
FY2019 −29.7% 4.79
FY2018 −34.5% (34.53)
FY2017 0.00% 682.35
FY2016 −682.4% (682.35)

Against its own ten years

Low −21,694.3% High 0.00%
Ten-year median −125.0%
Current reading's percentile 9

Return on invested capital against peers

What Return on invested capital is

Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.

TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)

The full definition of Return on invested capital →

More on PCSA